GlaxoSmithKline Hiccups Here And There, But Ultimately Makes You Rich

I’ve spent most of my day studying GlaxoSmithKline, the British version of Johnson & Johnson. I still haven’t finished my study of the company yet, but it looks like one of the few places in the large-cap sphere where you can get a fair shake and high annual income at today’s price in the low $50s.

The source of the opportunity is this: it tends to grow its profits at a slower rate than Johnson & Johnson (Johnson & Johnson will probably grow around 8-10% in the next decade, while GlaxoSmithKline figures to be closer to the 5-6% range), giving the company limited appeal to those who want to build wealth in a hurry. If you are trying to get rich in a hurry, why would you select a fairly valued GlaxoSmithKline growing at 5-6% annually when you could get your hands on a fairly valued Visa growing at 15-16% … Read the rest of this article!